Metagenomi Therapeutics, Inc. SEC filings MGX
Metagenomi Therapeutics, Inc. has 154 filings in SEC EDGAR's recent list, going back to Aug 16, 2019. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2025 | Nov 11, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 1, 2025 | Sep 29, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Other events
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Material agreement
|
Mar 17, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 17, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 16, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Other events
|
Dec 10, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Other events
|
Sep 3, 2024 | Sep 3, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Agreement ended, Results of operations, Regulation FD disclosure
|
May 1, 2024 | Apr 26, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2024 | Mar 27, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 13, 2024 | Feb 13, 2024 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MGX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1785279
- Former names
- Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.